Title: Dialysis Vascular Access The Achilles Heel Still Needs Fixing Lessons from the Dialysis Access Consortium DAC Clinical Trials
1Dialysis Vascular AccessThe Achilles Heel Still
Needs Fixing Lessons from the Dialysis Access
Consortium DAC Clinical Trials
- Harold I. Feldman, M.D., M.S.C.E.
- University of Pennsylvania
2Overview
- The epidemic of vascular access dysfunction
- Dialysis Access Consortium (DAC)
- Genesis and goal of DAC
- Synthetic graft study
- Native arteriovenous fistula study
- Insights and future directions
3Primary Patency - Grafts vs AVFs US DOPPS 1997-99
Prop. Failure-free
Adjusted RR1.22, plt0.01
Median survival (days) Grafts 176 AVFs 236
AVFs
Grafts
600
800
1000
VA Time (days)
4Synthetic Vascular Access Grafts
- Survival of Grafts
- Median unassisted survival 1 year
- Median cumulative patency lt2 years
- Require frequent patency restoring/maintaining
interventions - Pathology of Graft Failure
- 90 loss due to myointimal hyperplasia
- Smooth muscle and endothelial proliferaton
- Capillary growth with neointima
- Smooth muscle (PDGF and FGF) and endothelial
(VEGF) mitogens prominent
5Native Arteriovenous Fistulae
- Survival of Fistulae
- Excellent survival after successful maturation
- Substantial loss from thrombosis shortly after
placement - Pathology of Fistula Failure
- 10-30 fail due to early thrombosis
- Maturation rates and etiology not well-described
- Late stenosis, aneurysm
6Costs of Vascular Access Morbidity
- 10-15 hospitalization in ESRD related to access
dysfunction - 1994 - 14 -17 of all costs for hemodialysis
spent on vascular access? - 2003 - Annual costs well-exceed 1billion?
Feldman HI et al. 1996 ? USRDS 2005
7Todays Wisdom KDOQI 2006
- Fistula placement first
- Radiocephalic
- Brachiocephalic
- Transposed brachial basilic
- Prosthetic grafts if fistula not possible
- Forearm loop
- Forearm straight
- Upper arm
- Chest wall / lower extremity
- Regular surveillance of access function
- Avoid catheters
8(No Transcript)
9Trends in Access Type
Catheter
Fistula
Graft
USRDS ADR 2008 ESRD CPM
10(No Transcript)
11Access Complications
Catheter
Fistula
Graft
Note differences in the scales for the rates of
complications
USRDS ADR 2008 ESRD CPM
12Genesis and Goals of DAC
- Clinical practice principally has focused on
monitoring for and anatomically fixing access
failure Not on primary prevention - Identification of effective preventative
strategies to - Save resources
- Reduce morbidity
- Permit achievement of current access utilization
goals, i.e., stem the tide of increasing
utilization of dialysis catheters
13Two Concurrent DAC Trials
- Graft Trial
- Aggrenox (ERDP/ASA) for the Prevention of AV
Access Stenosis - Fistula Trial
- Clopidogrel for the Prevention of Early AV
Fistula Thrombosis
14Thirteen Primary Clinical Centers
- Broad geographic distribution in U.S.
- Urban and rural centers
- Academic and community practices
- Graft surgeries performed at 28 hospitals
- Involved 77 vascular access surgeons
- Dialysis was delivered at 88 facilities
15DAC Graft TrialRationale and Design
16Graft Trial Rationale and Goal
- Target
- Pharmacological prevention of myointimal
hyperplasia - Many agents considered
- Dipyridamole
- Fish oil
- HMG CoA reductase inhibitors
- ACE inhibitors
- Angiotensin AT1 receptor blockers
- Heparinoids / Pentosan phosphate
- Sirolimus
- Trapidil
- Tranilast
- Ticlopidine
- Clopidogrel
- Pentoxyphyllin
- Anti-VEGF (phase II)
17Dipyridamole and Vascular Disease
18Rationale for Dipyridamole (DP)
- DP inhibits VSMC proliferation in vitro
- DP inhibits stenosis after experimental arterial
injury in vivo - DP ASA inhibited late stenosis in coronary
artery bypass grafts and progression of
peripheral artery disease - ERDP reduced recurrent stroke risk
- ERDP equal to low dose ASA
- Additive benefit of combined ERDP ASA
- DP reduces AVG thrombosis in HD patients
19Graft Trial Overview
Access Placed
1st Intervention or Thrombosis
Site Loss
HD Starts
ERDP/ASA or Placebo
Monthly visits to monitor access problems,
adverse events and measure access flow rate
Randomize Start Drug
Primary Unassisted Patency
Cumulative Access Patency
Site Failure
20Graft Trial Eligibility Criteria
- New AV graft - any type or location
- Receiving chronic hemodialysis or anticipated to
start within 6 months - No contraindication to ERDP/ASA
- No concurrent use of anti-coagulants or
anti-platelet agents except ASA - No recent bleeding events
21Graft Trial Primary Outcome
- Primary unassisted graft patency
- Time from access surgery to first thrombosis or
procedure required to maintain or restore patency
22Graft Trial Secondary Outcomes
- Cumulative graft patency (i.e., irreparable
graft failure) - Patient survival
- Composite of patient survival or cumulative graft
patency
23DAC Graft Trial Results
24Graft Trial Enrollment and Follow-up
328 included in analysis of primary and secondary
outcomes
321 included in analysis of primary and secondary
outcomes
25Graft Characteristics
Characteristic ERDP/ASA N 318 Placebo N 326
Graft type,
ePTFE 93.7 93.3
Other synthetic material 5.3 5.2
Biograft 1.0 1.5
Graft location,
Forearm loop 50.3 47.2
Upper arm 42.1 45.7
Leg 5.3 5.8
Chest 1.3 0.6
Other 0.9 0.6
26DAC Graft TrialPrimary Outcome
27Graft Trial - One Year Primary Unassisted Patency
on Placebo 23
Predicted one-year patency 46
Primary Unassisted Patency
One-year patency 23
Median Patency 4.3 months
28Graft Trial - ERDP/ASA Increases Primary
Unassisted Patency
HR 0.82 95 CI 0.69 - 0.99 P0.034
ERDP/ASA
Primary Unassisted Patency
Placebo
29Percent of Patients Reaching the Primary Endpoint
Primary endpoint ERDP/ASA N 321 Placebo N 328
Overall failure of primary unassisted patency 80 84
30Percent of Patients in Each Component of the
Primary Endpoint
Primary endpoint ERDP/ASA N 321 Placebo N 328
Overall failure of primary unassisted patency 80 84
Thrombosis 40 43
Stenosis gt50 26 28
Infection 7 4
Failure to use graft by 12 wks 1 3
Other procedure 7 6
31Graft Trial - Secondary Outcomes
Secondary endpoints ERDP/ASA N 321 PlaceboN328 HR(95 CI) P-value
Cumulative graft failure 49 53 0.95(0.76, 1.19) 0.65
Death 27 31 0.97(0.72, 1.30) 0.84
Cumulative graft failure or death 61 63 0.97 (0.81, 1.22) 0.97
32Graft Trial - Adverse Events
33Graft Trial - Key Findings
- Primary failure rate 77 in the placebo group at
one year - Stenosis leading to thrombosis is the most common
cause of primary graft failure - ERDP/ASA produced a 18 reduction in the failure
rate of primary unassisted patency for new AV
grafts - No significant effect on cumulative graft patency
- No increase in bleeding, AEs, or including death
34Graft Trial - Clinical Implications
- Until now only procedure-based therapies were
effective at treating graft stenosis and
thrombosis - DAC Graft Trial heralds the first pharmacological
therapy effective to prolong graft patency - Findings support the use of ERDP/ASA to prolong
primary unassisted graft patency - 17 treated to prevent 1 primary graft failure at
one year - No increased bleeding risk
- Well tolerated
35DAC Fistula TrialRationale and Design
36Fistula Trial Rationale and Goals
- Target
- Pharmacological prevention of early
thrombosis - Agents considered
- Dipyridamole
- Aspirin
- Ticlopidine
37Trials of Anti-Platelet Agents to Prevent Early
Fistula Thrombosis
Adapted from Kaufman JS. Seminars in Dial 2000
13 40-46
38Clopidogrel
- Thienopyridine derivative that interferes with
ADP-mediated platelet activation - Inhibits release of platelet granule contents,
platelet-platelet interactions, and platelet
adhesion to endothelium - Tolerability and safety profile similar to
intermediate-dose aspirin
39Fistula Trial Overview
Fistula Creation
Clopidogrel or Placebo
Randomization and start of study drug
Patency Assessment Week 6
Suitability Ascertainment Month 5
Clopidogrel 300 mg loading dose 75 mg
daily dose
40Fistula TrialNine Clinical Centers
- Fistula surgeries at 27 hospitals
- Dialysis at 125 facilities
- Broad geographic distribution
- Urban and rural centers
- Academic and community practices
41Fistula TrialEligibility Criteria
- New upper extremity native AV fistula
- Chronic hemodialysis therapy or anticipated to
start chronic hemodialysis within 6 months - No contraindication to clopidogrel
- Able to discontinue anti-platelet agents or
anti-coagulants during study drug administration
42Fistula TrialPrimary Outcome
- Fistula patency at 6 weeks
- Presence of bruit throughout systole and diastole
detectable along the vein at least 8 cm proximal
to the AV anastomosis
43Fistula TrialSecondary Outcome
- Fistula suitability for dialysis
- Ability to use the fistula for dialysis for 8 of
12 sessions during a four week period with a
dialysis machine blood flow of ?300 ml/min - Ascertained during the 5th month following
fistula creation, or during 1st month of dialysis
if dialysis was initiated gt4 months after surgery
44DAC Fistula TrialPrimary Results
45Fistula TrialTrial Enrollment
- Began January, 2003
- Ended on 10/24/06 at the recommendation of the
DSMB after the 4th interim analysis - Early termination based on pre-defined stopping
rules - At termination of enrollment 877 subjects
randomized (1284 planned)
46Fistula Trial Enrollment Terminated Early for
Efficacy of the Intervention on the Primary
Outcome
Thrombosis at 6 weeks Clopidogrel 53
(12.2) Placebo 84 (19.5)
Dember L et al. JAMA 2008
47Fistula Trial Enrollment Terminated Early for
Efficacy of the Intervention on the Primary
Outcome
Thrombosis at 6 weeks Clopidogrel 53
(12.2) Placebo 84 (19.5)
Relative Risk 0.63 95 CI 0.46
0.97 P Value 0.018
Adjusted for interim analyses
Dember L et al. JAMA 2008
48Fistula Trial Secondary Outcome Suitability
for Dialysis
Dember L et al. JAMA 2008
49Fistula Trial Secondary Outcome Suitability
for Dialysis
Suitability ascertained in 758 of 877 subjects
(86)
Dember L et al. JAMA 2008
50Fistula Trial Secondary Outcome Suitability
for Dialysis
Unsuitable fistulas Clopidogrel 238 (62)
Placebo 222 (60)
Dember L et al. JAMA 2008
51Fistula Trial Secondary Outcome Suitability
for Dialysis
Unsuitable fistulas Clopidogrel 238 (62)
Placebo 222 (60)
Relative Risk 1.05 95 CI 0.94
1.17 P Value 0.40
Dember L et al. JAMA 2008
52DAC Fistula TrialAdverse Events
53Fistula Trial - No Safety Concerns
Clopidogrel Placebo
54Fistula Trial Findings
- Clopidogrel reduced the risk of early fistula
thrombosis, but did not increase the of
fistulas that became suitable for use - Short-term use of clopidogrel appears safe
55DAC Fistula TrialInterpretation and Implications
56Fistula Trial - Implications
- A very high proportion of new fistulae do not
mature - Patency is necessary, but not sufficient for
fistula maturation - Early fistula patency - a poor proxy for
suitability - Processes not affected by clopidogrel are likely
to be important for maturation - Routine use of clopidogrel to prevent early
failure of new fistulae not warranted
57What have we learned?Where to from here?
58Global Lessons Learned
- Access failures continue to occur at an alarming
rate even in the idealized research setting - Current rates of fistula failures and a dearth of
effective interventions emphasize the risks of an
overly narrow focus on fistula placement - Do we need to rethink the strategy of Fistula
First? Is Catheter Last more appropriate?
59Global Lessons Learned
- We need more comprehensive access strategies
recognizing the cumulative individual-level
exposure to varied access types over time that
optimize care through minimization of risk and
toxicity - Broader performance metrics are needed that do
not focus solely on the proportion of any one
access type
60Lessons Learned - Fistulae
- Expanded selection criteria for fistula placement
probably account, in part, for continued poor
outcomes - The pathophysiology underlying failure of fistula
maturation is not well-enough understood - Peri-operative fistula patency necessary, but not
sufficient for fistula maturation - Early imaging and anatomical correction of
failing fistulas may hold particular promise
61Fistulae - Focus of Future Efforts
- Elucidating mechanisms underlying maturation
failure for new targets for intervention - Assessing the prognostic value of early imaging
algorithms - Developing predictive models to reduce rate of
fistula non-maturation - NIH-NIDDK Arteriovenous Fistula Maturation Cohort
Study initiated summer 2008
62Lessons Learned - Grafts
- Anti-hyperplasia agents appear to have the
ability to reduce graft dysfunction, but impact
to date has been small - A shift from restorative therapies to prevention
of graft stenosis appears increasingly feasible - A focus on prolonging cumulative patency (grafts)
should not detract from targeting reductions in
recurrent access dysfunction (chronic disease
model)
63Grafts - Focus of Future Efforts
- Examine other pharmacological agents/strategies
to shift from procedure-based treatment of access
failure to preventive and safe pharmacological
therapies
64Lessons Learned - Catheters
- Use continues to rise as does associated
toxicities. We can not afford to exclude this
observation from our metrics of quality
performance
65Catheters - Focus of Future Efforts
- Global risk minimization strategies
- Better catheter technologies that reduce
infection risk and vascular trauma
66Acknowledgments
- NIDDK / NIH
- Bristol-Myers Squibb / Sanofi-Aventis
- Nephrologists, vascular surgeons and dialysis
unit staff - Participating patients
67- Clinical Centers
Principal Investigators - Boston Univ / Baystate Med Ctr L. Dember, G.
Braden - Charlestown Area MC A. Rahman, B. Reyes
- Duke University A. Greenberg
- Emory University J. Work
- Maine Medical Center J. Himmelfarb
- St. Louis University K. Martin
- Tyler Nephrology Assoc, TX J. Cotton
- Univ Alabama Birmingham M. Allon
- Univ Iowa / Renal Care Assoc, Peoria IL B.
Dixon, T. Pflederer - Univ Texas S.W. / Baylor Med Ctr M.
Vazquez, A. Fenves - Vanderbilt University T.A. Ikizler
- Vascular Surgery Assoc, LA J. McNeil
- Washington University J. Delmez
- Data Coordinating Center
- Cleveland Clinic Foundation G. Beck
- Steering Committee Chair
- Harold Feldman, Univ. of Pennsylvania
- NIDDK
DAC Study Sites
68Percent of Patients Having Stenosis gt50 at
Primary Endpoint
Primary Endpoint ERDP/ASA N 321 Placebo N 328
Overall failure of primary unassisted patency 80 84
Thrombosis 40 43
Stenosis gt50 26 28
Infection 7 4
Failure to use graft by 12 wks 1 3
Other procedure 7 6
Stenosis gt50 with or without thrombosis 47 51
69Fistula TrialRationale for Outcomes
- Patency
- Clinically important
- Outcome closely related to biological effect of
intervention - Ascertainment highly feasible
- Supportive pilot data
- Suitability
- Clinically important